People: Cephalon, Inc. (CEPH.O)

CEPH.O on Nasdaq

65.78USD
9 Feb 2010
Price Change (% chg)

$0.78 (+1.20%)
Prev Close
$65.78
Open
--
Day's High
$66.50
Day's Low
$64.64
Volume
1,669,476
Avg. Vol
1,572,809
52-wk High
$79.68
52-wk Low
$52.55

view people for:

Summary

Name Age Since Current Position
Baldino, Frank 56 1999 Chairman of the Board, Chief Executive Officer
Groenhuysen, Wilco 52 2010 Chief Financial Officer, Executive Vice President
Buchi, J. Kevin 54 2010 Chief Operating Officer
Savini, Carl 59 2006 Executive Vice President, Chief Administrative Officer
Vaught, Jeffry 58 2008 Executive Vice President, Chief Scientific Officer
Baldassano, Valli 48 2007 Executive Vice President, Chief Compliance Officer
Pappert, Gerald 45 2008 Executive Vice President, General Counsel, Company Secretary
Grebow, Peter 62 2005 Executive Vice President - Worldwide Technical Operations
Russell, Lesley 48 2008 Executive Vice President, Chief Medical Officer
Aragues, Alain 58 2010 Executive Vice President and President, Cephalon Europe
Egan, William 64 1988 Director
Greenacre, Martyn 67 1992 Director
Moley, Kevin 62 2006 Director
Sanders, Charles 77 2001 Director
Wilensky, Gail 66 2002 Director
Winger, Dennis 62 2003 Director
Kailian, Vaughn 64 2005 Director
» Insider Trading

Biographies

Name Description
Baldino, Frank Dr. Frank Baldino is Chairman of the Board, Chief Executive Officer of Cephalon, Inc. He founded Cephalon and has served as Chief Executive Officer and director since the Company's inception. He was appointed Chairman of the Board of Directors in 1999. He currently serves as a director of Acusphere, Inc., a drug delivery company, NicOx S.A., a company engaged in the research, development and commercialization of nitric oxide therapeutics, and Pharmacopeia, Inc., a developer of proprietary technology platforms for pharmaceutical companies. Dr. Baldino also holds several adjunct academic appointments and is a trustee of Temple University.
Groenhuysen, Wilco Mr. Wilco Groenhuysen is the Chief Financial Officer, Executive Vice President of Cephalon, Inc. He is responsible for Worldwide Finance, Commercial Operations and Risk Management. Mr. Groenhuysen joined Cephalon in August 2007 as SVP of Finance. Prior to Cephalon, he was CFO and Sr. Vice President of Phillips Electronics North America, where he served in various finance roles over his 20 years with the company.
Buchi, J. Kevin Mr. J. Kevin Buchi is the Chief Operating Officer of Cephalon, Inc. He has held the position of Chief Financial Officer since 1996. Between 1985 and 1991, Mr. Buchi served in a number of financial positions with E.I. du Pont de Nemours and Company. Mr. Buchi received a master of management degree from the J.L. Kellogg Graduate School of Management, Northwestern University in 1982. Mr. Buchi serves as a member of the board of directors of Lorus Therapeutics Inc., a publicly-traded Canadian biotechnology company, and Encysive Pharmaceuticals Inc., a publicly-traded pharmaceutical company.
Savini, Carl Mr. Carl A. Savini joined Cephalon, Inc. in June 1993 and, since February 2006, he has served as Executive Vice President and Chief Administrative Officer. Mr. Savini has served in various capacities with the Company, including Senior Vice President, Administration and Senior Vice President, Human Resources. From 1983 to 1993, Mr. Savini was employed by Bristol-Myers Squibb Company and from 1981 to 1983 he was employed by Johnson & Johnson's McNeil Pharmaceuticals. Mr. Savini graduated from The Pennsylvania State University and received a master of business administration degree from La Salle College.
Vaught, Jeffry Dr. Jeffry L. Vaught joined Cephalon, Inc. in August 1991 and, since August 2008, he has served as Executive Vice President and Chief Scientific Officer responsible for directing Cephalon's research operations. Prior to joining Cephalon, Dr. Vaught was employed by the R. W. Johnson Pharmaceutical Research Institute, a subsidiary of Johnson & Johnson. Dr. Vaught received a Ph.D. in pharmacology from the University of Minnesota.
Baldassano, Valli Ms. Valli F. Baldassano joined Cephalon, Inc. in October 2007 as Executive Vice President and Chief Compliance Officer. From April to September 2007, Ms. Valli Baldassano served as Partner with Fox Rothschild LLP in Philadelphia where she was a member of the litigation department and the founding member of the White Collar Compliance and Defense Practice Group. Between January 2004 and March 2007, Ms. Baldassano served as Vice President Global Compliance for Schering-Plough. Between 1999 and 2003, Ms. Baldassano service as Senior Director, Global Compliance and Associate General Counsel for Pharmacia. Between 1990 and 1998, Ms. Baldassano was with the U.S. Attorney's Office in the Eastern District of Pennsylvania. Ms. Baldassano graduated from Georgetown University and received her J.D. from Syracuse University.
Pappert, Gerald Mr. Gerald J. Pappert joined Cephalon, Inc. in May 2008 as Executive Vice President and General Counsel. In October 2008, Mr. Pappert assumed the responsibilities of the Company Secretary. Prior to coming to Cephalon, Mr. Pappert was a partner with Ballard Spahr Andrews & Ingersoll LLP in Philadelphia, PA, where he was a member of the Litigation Department. From 2003 to 2005, Mr. Pappert was the Commonwealth of Pennsylvania Attorney General. From 1997 to 2003, he held the position of First Deputy Attorney General of Pennsylvania. Mr. Pappert is a graduate of Villanova University and earned his Juris Doctorate from the University of Notre Dame Law School.
Grebow, Peter Dr. Peter E. Grebow joined Cephalon, Inc. in January 1991, and since February 2005 has served as Executive Vice President, Worldwide Technical Operations. Dr. Grebow also has served as Senior Vice President, Worldwide Technical Operations, Senior Vice President, Business Development, and Vice President, Drug Development. From 1988 to 1990, Dr. Grebow served as Vice President of Drug Development for Rorer Central Research, a division of Rhone-Poulenc Rorer Pharmaceuticals Inc., a pharmaceutical company. Dr. Grebow received a Ph.D. in chemistry from the University of California, Santa Barbara.
Russell, Lesley Dr. Lesley Russell joined Cephalon, Inc. in January 2000, and, since August 2008, she has served as Executive Vice President and Chief Medical Officer. From November 2006 to August 2008, Dr. Russell served as Executive Vice President, Worldwide Medical and Regulatory Operations. From January 2000 to August 2006, Dr. Russell was Senior Vice President of Worldwide Clinical Research with the Company. Dr. Russell came to Cephalon in January 2000 from US Bioscience Inc./Medimmune Oncology, where she was Vice President Clinical Research, responsible for directing and implementing the clinical programs in oncology and HIV research. Prior to joining US Bioscience, Dr. Russell was Director of Clinical Research at USB Pharma Ltd, the European subsidiary of US Bioscience. Before her work at USB Pharma, Dr. Russell was a Clinical Research Physician at Eli Lilly UK, responsible for the oncology clinical trial program in the UK. Dr. Russell was Medical Director at Amgen UK from May 1992 to May 1995. Before joining the pharmaceutical industry, Dr. Russell was trained in Hematology/Oncology at Royal Infirmary of Edinburgh, and Royal Hospital for Sick Children Edinburgh UK and was a Research Fellow at University of Edinburgh Faculty of Medicine. Dr. Russell received MB.Ch.B. from University of Edinburgh, Scotland, Faculty of Medicine and is a member of the Royal College of Physicians, UK.
Aragues, Alain Mr. Alain Aragues is the Executive Vice President and President, Cephalon Europe of Cephalon, Inc. Mr. Aragues joined Cephalon in 2002 to lead the company's expansion in France following its 2001 acquisition of Group Lafon and was appointed President of Cephalon Europe in 2005.
Egan, William Mr. William P. Egan is a Director of Cephalon Inc. Since 1988. Mr. Egan is a founder and general partner of Alta Communications, a venture capital firm. He founded Alta's predecessor firm, Burr, Egan, Deleage & Co. in 1979 and has identified and backed several of America's leading growth companies in the communications and information industries. Mr. Egan currently serves as a director of CRH plc, a building materials supply company.
Greenacre, Martyn Mr. Martyn D. Greenacre is a Director of Cephalon Inc. Since 1992. Since July 2004, Mr. Greenacre has served as Chairman of BMP Sunstone Corporation, a pharmaceutical company. Mr. Greenacre also has served since 2002 as Chairman of Life Mist Technologies, Inc., a fire suppression equipment company. From 1997 to 2001, Mr. Greenacre served as Chief Executive Officer and director of Delsys Pharmaceutical Corporation, a formulation and drug delivery system company. From 1993 to 1997, Mr. Greenacre served as President and Chief Executive Officer and as a director of Zynaxis Inc., a biopharmaceutical company. From 1989 to 1992, Mr. Greenacre was Chairman Europe, SmithKline Beecham Pharmaceutical company. He joined SmithKline & French in 1973, where he held positions of increasing responsibility in its European organization. Mr. Greenacre currently serves as a director of Acusphere, Inc., a drug delivery company and Curis, Inc., a biotechnology company.
Moley, Kevin Amb. Kevin E. Moley is Director of Cephalon Inc. since 2006. He is currently serves as Chairman of the Board of Project Concern International, a not-for-profit organization based in San Diego, California, that provides poverty and health care solutions in eleven countries serving over three million people. In addition, Ambassador Moley currently serves as a director of Aperture Health, Inc., a provider of on-line health and wellness services. Ambassador Moley served as the U.S. Permanent Representative to the United Nations and Other International Organizations in Geneva from September 2001 to April 2006. Ambassador Moley also served in the administration of George H.W. Bush as an Assistant Secretary of the U.S. Department of Health and Human Services (HHS) from 1989 to 1992 and as the Deputy Secretary of HHS from 1992 to 1993. In addition to his government service, Ambassador Moley was President and Chief Executive Officer of Integrated Medical Systems Inc. from 1996 to 1998 and was a Senior Vice President of PCS Health Systems, Inc. from 1993 to 1996. Ambassador Moley previously served as a member of the Cephalon Board of Directors from 1994 to 2001
Sanders, Charles Dr. Charles A. Sanders is a Director of Cephalon Inc. Since 2001. Dr. Sanders is retired from Glaxo, Inc., where he served as Chief Executive Officer from 1989 through 1994 and Chairman of the Board from 1992 through 1995. He also has served on the Board of Directors of Glaxo plc. Previously, Dr. Sanders held a number of positions at Squibb Corporation. Dr. Sanders currently serves as Chairman of the Board of Vertex Pharmaceuticals, a biotechnology company. He also serves as a director of Genentech, Inc., a biopharmaceutical company, Biodel Inc., a specialty pharmaceutical company, and Icagen, Inc., a biopharmaceutical company.
Wilensky, Gail Dr. Gail R. Wilensky is a Director of Cephalon Inc. since 2002. Dr. Wilensky serves as a Senior Fellow at Project HOPE, an international health education foundation, which she joined in 1993 and President of the Defense Health Board, a federal advisory committee for the Department of Defense. From 1997 to 2001, Dr. Wilensky chaired the Medicare Payment Advisory Committee, which advises Congress on all issues relating to Medicare. In November 2004, Dr. Wilensky was appointed as the Vice Chair of the Maryland Health Care Commission. In December 2006, Dr. Wilensky was selected to co-chair a Congressionally-mandated task force on the future of military health care. Dr. Wilensky also is an elected member of the Institute of Medicine and its Governing Council, and serves as a trustee of the Combined Benefits Fund of the United Mineworkers of America and the National Opinion Research Center of the University of Chicago. Dr. Wilensky currently serves as a director of Gentiva Health Services, a specialty pharmaceutical and home health care company, Quest Diagnostics, Inc., a leading provider of diagnostic testing, information and services, SRA International, Inc., a provider of information technology services to the government, and UnitedHealth Group, a health care company.
Winger, Dennis Mr. Dennis L. Winger is a Director of Cephalon Inc. since 2003. Mr. Winger is designated as the Audit Committee Financial Expert. In 2008, Mr. Winger retired from Applera Corp., a life sciences company, where he was Senior Vice President and Chief Financial Officer responsible for developing financial and business strategies. He served as a member of Applera's Executive Committee. From 1989 to 1997, Mr. Winger served as Senior Vice President, Finance and Administration, and Chief Financial Officer of Chiron Corporation. From 1982 to 1989, Mr. Winger was with Cooper Companies, Inc., where he held positions of increasing responsibility, including that of Chief Financial Officer. Prior to this, Mr. Winger was with Continental Can Company holding a number of positions including Head of Finance for its international division and General Manager of its Latin American Operations. Mr. Winger currently serves as a director of Cell Genesys, Inc., a pharmaceutical company.
Kailian, Vaughn Mr. Vaughn M. Kailian is a Director of Cephalon Inc. Since 2005. Mr. Kailian is a Managing Director of MPM Capital LP, a leading healthcare venture capital firm. He was Vice Chairperson of the Board of Directors of Millennium Pharmaceuticals, Inc. from February 2002 until December 2004. He served as CEO, President and Director of COR Therapeutics, Inc., a biotechnology company, from 1990 until its acquisition by Millennium in 2002. Prior to this, Mr. Kailian was employed by Marion Merrell Dow, Inc., a pharmaceutical company, and its predecessor companies, in various international and U.S. management, marketing and sales positions from 1967 to 1990, including President and General Manager, Merrell Dow USA and Corporate Vice President of Global Commercial Development, Marion Merrell Dow, Inc. Mr. Kailian currently serves on the board of directors of NicOx, S.A., a pharmaceutical company. He is also a director of BIO Ventures for Global Health, a non-profit organization, and BIO (the Biotechnology Industry Organization).

Basic Compensation

Name Fiscal Year Total
Baldino, Frank 14,496,500
Groenhuysen, Wilco --
Buchi, J. Kevin 3,378,460
Savini, Carl 3,387,820
Vaught, Jeffry 3,139,850
Baldassano, Valli --
Pappert, Gerald --
Grebow, Peter 3,298,490
Russell, Lesley --
Aragues, Alain --
Egan, William --
Greenacre, Martyn --
Moley, Kevin --
Sanders, Charles --
Wilensky, Gail --
Winger, Dennis --
Kailian, Vaughn --
As Of 30 Dec 2008

Options Compensation

Name Options Value
Baldino, Frank 1,331,000 28,822,110
Groenhuysen, Wilco 0 0
Buchi, J. Kevin 285,646 5,506,440
Savini, Carl 50,125 1,415,210
Vaught, Jeffry 201,000 7,063,530
Baldassano, Valli 0 0
Pappert, Gerald 0 0
Grebow, Peter 231,726 2,082,580
Russell, Lesley 0 0
Aragues, Alain 0 0
Egan, William 0 0
Greenacre, Martyn 0 0
Moley, Kevin 0 0
Sanders, Charles 0 0
Wilensky, Gail 0 0
Winger, Dennis 0 0
Kailian, Vaughn 0 0

Insider Trading

Name Shares Traded Price
BALDINO FRANK JR 502 $64.80
BALDINO FRANK JR 8,016 $59.75
ROCHE ROBERT P JR 1,504 $59.75
VAUGHT JEFFRY L 1,504 $59.75
RUSSELL LESLEY 1,157 $59.75
BUCHI J KEVIN 1,241 $59.75
GREBOW PETER E 1,522 $59.75
SAVINI CARL A 1,532 $59.75
RUSSELL LESLIE ARTHUR 1,157 $59.13
BALDINO FRANK JR 8,022 $59.13
ROCHE ROBERT P JR 1,503 $59.13
BUCHI J KEVIN 1,241 $59.13
BALDASSANO VALLI F 287 $59.13
VAUGHT JEFFRY L 1,503 $59.13
GREBOW PETER E 1,522 $59.13
SAVINI CARL A 1,532 $59.13
ROCHE ROBERT P JR 1,503 $58.94
BALDASSANO VALLI F 1,147 $58.94
GREBOW PETER E 1,522 $58.94
RUSSELL LESLEY 1,157 $58.94
BUCHI J KEVIN 1,241 $58.94
SAVINI CARL A 1,532 $58.94
BALDINO FRANK JR 8,022 $58.94
VAUGHT JEFFRY L 1,503 $58.94
PAPPERT GERALD J 1,185 $58.94
» Full list on Insider Trading
view people for: